Under FDA, Unapproved Peptides Likely to Become More Widely Available

JAMA 2026

View at publisher
Authors: Rita Rubin
DOI: 10.1001/jama.2026.6388
Cited by: 1

Abstract

This Medical News article discusses the US Food and Drug Administration’s plans to increase the availability of unapproved peptides for which there is little evidence of safety and efficacy.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Biosimilars and Bioanalytical Methods Pharmaceutical studies and practices

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
22
Pages
1920–1920
Publication date
15 May 2026
Language
EN